← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry
TRPHARM sodium thiosulfate compassionate use program
Also known as: Sodium Thiosulfate, STS, TRP-STS-001, Fennec Pharma, NCT04132882
TRPHARM
Company
TRPHARM
Program Type
Therapeutic
Modality
Small Molecule
Stage
Expanded Access
Status
Active
Target Gene
—
Route / Mode
Intravenous infusion
Confidence
84%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
Turkey
Population
pediatric, cisplatin-ototoxicity, hepatoblastoma, expanded-access
Trial IDs
1
Mechanism
Intravenous sodium thiosulfate access program for protection from cisplatin-induced hearing loss in children with standard-risk hepatoblastoma.
Indications
Notes
Split from the mixed sodium-thiosulfate record. This is a TRPHARM-sponsored expanded-access/compassionate-use program with Fennec listed as collaborator, distinct from the terminated Thomas Jefferson intratympanic STS pilot.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, stage, status, route, populationTags...
IDs: NCT04132882, TRP-STS-001
Key Events
Clinical Trials (1)
Data Checks
expanded-access-programsplit-from-mixed-sodium-thiosulfate-record
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2